… Tyrosine kinase receptors are involved in cancer cell proliferation, angiogenesis, and
lymphangiogenesis. Several tyrosine kinase inhibitors … and stabilize the disease. Lenvatinib and …

… Cancer Center’s experience with the off-label use of these tyrosine kinase inhibitors for DTC…
treated outside of a clinical trial with a tyrosine kinase inhibitor (TKI) from 2006 to 2008 were …

… The described limited treatment choices for each histological type of thyroid cancer have
aroused the need for a novel therapeutic strategy, and tyrosine kinase inhibitors (TKIs) have …

… tyrosine kinases in the pathogenesis of thyroid carcinoma was discovered. Tyrosine kinase
inhibitors … growth factors leading to the inhibition of tumor cells growth and divisions [Citation…

… cells: follicular thyroid cells and parafollicular C … of thyroid malignancies and including
papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), poorly differentiated thyroid cancer (…

… tyrosine kinases, specific mutations, and genetic rearrangements that are either FDA approved
for thyroid cancer or of interest in treating this disease… expression of thyroid-specific genes…

… advanced or metastatic differentiated thyroid cancer (DTC) that is refractory to radioiodine
(RAI) remains a therapeutic challenge. The multi-tyrosine kinase inhibitors (TKIs) sorafenib …

… in the pathogenesis of many types of cancer. These receptors, … Tyrosine kinase inhibitors
(TKIs) affect TK dependent … and thereby inhibiting the growth and spread of several cancers. …

… Thyroid pathology is the most frequent form of endocrinopathy during tyrosine kinase inhibitor
… In patients with intact thyroid gland prior to TKI treatment, incidence of dysthyroidism is 30–…

… Table 2 Tyrosine kinase inhibitors tested in thyroid cancers: the table summarize
molecular targets of each compound and its label for the use in TCs in clinical practice. …